Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

M. L. Rothenberg1 J. V. Cox2 C. Butts3 M. Navarro4 Y.-J. Bang5 R. Goel6 S. Gollins7 L. L. Siu8 S. Laguerre9 and D. Cunningham10

首页> 外文期刊>Annals of Oncology >Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

【24h】

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

机译：卡培他滨加奥沙利铂（XELOX）与5-氟尿嘧啶/亚叶酸加奥沙利铂（FOLFOX-4）作为转移性结直肠癌的二线治疗：一项随机的非III期临床研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy.

机译：背景：为了证明卡培他滨加奥沙利铂（XELOX）与5-氟尿嘧啶/亚叶酸和奥沙利铂（FOLFOX-4）作为二线治疗在以伊立替康为基础的化疗后转移性结直肠癌患者中的非劣效性。

著录项

来源
《Annals of Oncology》 |2008年第10期|1720-1726|共7页
作者
M. L. Rothenberg1 J. V. Cox2 C. Butts3 M. Navarro4 Y.-J. Bang5 R. Goel6 S. Gollins7 L. L. Siu8 S. Laguerre9 and D. Cunningham10;
展开▼
作者单位

Division of Hematology/Oncology Vanderbilt-Ingram Cancer Center Nashville USA;

Department of GI Oncology Texas Oncology PA US Oncology Research Dallas TX USA;

Department of Oncology Cross Cancer Institute Edmonton Alberta Canada;

Department of Oncology Hospital Duran I Reynals Barcelona Spain;

Department of Oncology Seoul National University Hospital Seoul Republic of Korea;

Department of Medicine The Ottawa Hospital Ottawa Ontario Canada;

Department of Medicine North Wales Cancer Treatment Centre Glan Clwyd Hospital Rhyl UK;

Department of Medical Oncology Princess Margaret Hospital Toronto Ontario Canada;

Department of Biostatistics F. Hoffmann-La Roche Basel Switzerland;

Department of Medicine The Royal Marsden Hospital Sutton UK;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. [J] . Rothenberg ML, Cox JV, Butts C, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第10期

机译：卡培他滨加奥沙利铂（XELOX）与5-氟尿嘧啶/亚叶酸加奥沙利铂（FOLFOX-4）作为转移性结直肠癌的二线治疗：一项III期非劣效性随机研究。
2. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. [J] . Cassidy J, Clarke S, Diaz-Rubio E, Journal of Clinical Oncology . 2008,第12期

机译：卡培他滨加奥沙利铂与氟尿嘧啶/亚叶酸加奥沙利铂作为转移性结直肠癌的一线治疗的随机III期研究。
3. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [J] . J Souglakos, N Androulakis, K Syrigos, British Journal of Cancer . 2006,第6期

机译：FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）与FOLFIRI（亚叶酸，5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）
4. Effect of the Preventive Herbal Therapy Using Dai-kenchu-to on Intestinal Obstruction Following Curative Resection for Colorectal Cancer: Prospective, Randomized Study [C] . K. Takagi, H. Nagata, T. Horie, International Society of University Colon and Rectal Surgeons . 2006

机译：用傣族癌对肠梗阻对结直肠癌治疗肠梗阻的预防性草药治疗的影响：前瞻性，随机研究
5. FOLFOXIRI (folinic acid 5-fluorouracil oxaliplatin and irinotecan) vs FOLFIRI (folinic acid 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [O] . J Souglakos, N Androulakis, K Syrigos, 2006

机译：FOLFOXIRI（亚叶酸5-氟尿嘧啶奥沙利铂和伊立替康）与FOLFIRI（亚叶酸5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）
6. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [O] . Souglakos, J, Androulakis, N, Syrigos, K, 2006

机译：FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）与FOLFIRI（亚叶酸，5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅